Searchable abstracts of presentations at key conferences in endocrinology

ea0007p209 | Steroids | BES2004

The effect of adrenalectomy on 11beta-hydroxylase(CYP11B1) and aldosterone synthase (CYP11B2) gene expression in the hippocampus

Ye P , Kenyon C , Nichol K , MacKenzie S , Fraser R , Seckl J , Connell J , Davies E

11Beta-Hydroxylase and aldosterone synthase catalyse the synthesis of corticosterone and aldosterone in the rat adrenal cortex and are encoded by the CYP11B1 and CYP11B2 genes respectively. These genes are also expressed in distinct regions of the CNS and cardiovascular system where they may play a key role in behavioural response and blood pressure homeostasis. However, it is unclear whether this extra-adrenal expression is regulated by, or contributes to, circulating levels ...

ea0084op-01-04 | Oral Session 1: Topic Highlights | ETA2022

Selenoprotein deficiency disorder predisposes to aortic aneurysm formation

Schoenmakers Erik , Marelli Federica , Jorgensen Helle , Edward Visser W. , Moran Carla , Groeneweg Stefan , Avalos Carolina , Figg Nichola , Finigan Alison , Wali Neha , Agostini Maura , Wardle-Jones Hannah , Lyons Greta , Rusk Rosemary , Gopalan Deepa , Johannes Visser Jacob , Goddard Martin , Nashef Samer , Heijmen Robin , Clift Paul , Sinha Sanjay , Busch-Nentwich Elisabeth , Ramirez-Solis Ramiro , Persani Luca , Bennett Martin , Chatterjee Krishna

Objectives: Mutations in SECISBP2 cause deficiency of selenoproteins, resulting in a multisystem disorder with abnormal circulating thyroid hormone and selenium levels and features due to lack of specific selenoproteins or loss of antioxidant selenoenzymes. Having observed early-onset, aneurysmal thoracic aortic dilatation in four patients with this disorder, we studied zebrafish and murine Secisbp2 mutant models to determine whether the aortic phenotype and selenopro...

ea0077p80 | Neuroendocrinology and Pituitary | SFEBES2021

ACROBAT Advance: progress report on a study of long-term safety and efficacy of paltusotine for the treatment of acromegaly

Randeva Harpal , R . Gadelha Monica , Gordon Murray B. , Mezosi Emese , Doknic Mirjana , Toth Miklos , Boguszewski Cesar , Jochelson Theresa , Nichols Melissa , Luo Rosa , Madan Ajay , Ferrara-Cook Christine , Krasner Alan , Casagrande Alessandra , Scott Struthers R.

Paltusotine is a once-daily, oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, which is in clinical development for the treatment of acromegaly. Maintenance of insulin-like growth factor 1 (IGF-1) control and toleration was demonstrated in phase 2 studies evaluating paltusotine in biochemically controlled (IGF-1 ≤1xULN) [ACROBAT Evolve (NCT03792555)] and uncontrolled (1> IGF-1 ≤2.5xULN) [ACROBAT Edge (NCT03789656)] patients with acromegaly ...

ea0081oc4.6 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

ACROBAT advance: once daily, oral paltusotine treatment maintained long-term igf-1 at levels previously achieved with injectable long-acting somatostatin receptor ligands (LA-SRLs)

Gadelha Monica R , Randeva Harpal , Gordon Murray B , Mezosi Emese , Doknic Mirjana , Toth Miklos , Boguszewski Cesar L , Nichols Melissa , Jochelson Theresa , Henley Scott , Patel Meenal , Mendez Debbie Koh , Ferrara-Cook Christine , Krasner Alan , Casagrande Alessandra , Struthers R Scott

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

ea0011s58 | Steroid hormone receptors | ECE2006

The ups and downs of nuclear receptor action in fat and fertility

Parker M , Christian M , Seth A , Kiskinis E , Debevec D , Nichol D , Tullet J , Steel J , White R

Nuclear Receptors control many developmental and physiological processes by regulating the expression of networks of genes. Their ability to activate or repress gene transcription depends on the recruitment of coactivators and corepressors that function as scaffolds for the binding of chromatin remodelling enzymes. RIP140 is a ligand dependant corepressor for most, if not all, nuclear receptors with key roles in energy homeostasis and reproduction.RIP140...

ea0051oc4.4 | Oral Communications 4 | BSPED2017

The MAPK effector B-Raf is essential for hypothalamic-pituitary axis development and activating mutations in BRAF cause congenital hypopituitarism

Kyprianou Nikolina , Gregory Louise , Vignola Maria Lillina , Nichols James , Marinelli Eugenia , Gualtieri Angelica , Scagliotti Valeria , Besser Rachel , Camper Sally , Davis Shannon , Hogler Wolfgang , Temple Karen , Davies Justin H , Casado Pedro , Rajeeve Vinothini , Cutillas Pedro , Gevers Evelien , Dattani Mehul , Gaston-Massuet Carles

Germline mutations in BRAF and other components of the RAS/MAPK pathway are found in RASopathies, whose features include short stature and pubertal delay. The underlying mechanism of endocrinopathies in RASopathies has not been fully elucidated. We report four BRAF mutations (two of which are novel) in four children with congenital hypopituitarism and RASopathy features. To demonstrate the functional role of the variants we performed phosphoproteomic analyses...

ea0008p23 | Cytokines and growth factors | SFE2004

Variability in IGF-I assay performance undermines its contribution to the management of GH axis disorders

Pokrajac-Simeunovic A , Wark G , Wieringa GE , Trainer PJ

IGF-I is a marker of activity of the growth axis. It is accepted that the interpretation of IGF-I values requires age- and gender-specific reference ranges (RR).We have studied IGF-I assay performance by circulating 2 blood samples with different clinical scenarios to 23 centers [IDS-OCTEIA (n=2), DPC-Immulite (3), DPC-Immulite 2000 (4), in-house RIA (1), Nichols-Advantage (10) and Nichols-IRMA (3)] participating in the UK-NEQAS IGF-I scheme. Participant...

ea0016p439 | Neuroendocrinology | ECE2008

A comparison between three automated chemiluminescence assays for growth hormone: on the use of recombinant hGH as a primary calibrant

Arafat Ayman M , Mohlig Matthias , Weickert Martin O , Perschel Frank H , Purschwitz Johannes , Spranger Joachim , Strasburger Christian J , Schofl Christof , Pfeiffer Andreas FH

Objectives: GH measurements during OGTT have profound effects on therapy and follow-up management of acromegaly. To minimize the discordance between immunoassays, it is recommended to calibrate them using 22 kDa-GH-preparation instead of the use of pituitary-derived calibrants. The aim of our study was to evaluate the between-method discrepancies in GH determinations by assays using different calibrants considering further confounders like age, gender, and BMI.<p class="ab...

ea0014oc8.1 | Neuroendocrinology clinical | ECE2007

Growth hormone response during OGTT: the impact of assay method, gender and BMI on the estimation of reference values in patients with acromegaly and in healthy controls

Arafat Ayman M , Möhlig Mathias , Weickert Martin O , Perschel Frank H , Purschwitz Johannes , Spranger Joachim , Strasburger Christian J , Schöfl Christof , Pfeiffer Andreas FH

Objectives: Besides the measurement of IGF-1, GH suppression during OGTT to assess the biochemical status in acromegaly is recommended. However, as a consequence of the development of highly sensitive and specific GH assays a critical re-evaluation of the criteria for the diagnosis and follow-up management of acromegaly is mandatory. The aim of our study was to evaluate the between-method discrepancies in GH determinations by different immunoassays considering further confound...

ea0016p49 | Adrenal | ECE2008

Evaluation of aldosterone to renin concentration ratio as a reliable screening parameter for primary aldosteronism applying currently available assays

Unger Nicole , Deutschbein Timo , Brocker-Preuss Martina , Ueberberg Bianca , Hinrichs Jakob , Walz Martin K , Schmid Kurt W , Mann Klaus , Petersenn Stephan

Plasma aldosterone concentration (PAC) to active renin concentration (ARC) ratio (ARR) is an established screening tool for primary aldosteronism. Previously we provided reliable cut-offs measuring PAC by a radioimmunoassay (RIA; Byk&DiaSorin) und ARC by an established immunoluminometric assay (Nichols Institute Diagnostics). Since the latter one is not longer available, we aimed to establish cut-offs for currently available assays.One hundred seven ...